MYCOSES STUDY GROUP EDUCATION AND RESEARCH CONSORTIUM (EIN 464283467) - Form 990 Financial Analysis & Trantor Score

🔒

Tuckman-Chang Vulnerability Assessment

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2013

Legal Domicile

Principal Officer

CAROLYNN JONES DNP

Phone

2056120421

Tax Period

2024-01-01 to 2024-12-31

MYCOSES STUDY GROUP EDUCATION AND RESEARCH CONSORTIUM, founded in 2013, is a small nonprofit in the Medical Research sector that reported $384K in total revenue in fiscal year 2018. Revenue surged 435% from the prior year, signaling strong growth momentum. The organization ran a surplus of $132K, a strong 34% operating margin.

Mission

TO PROVIDE CONTINUING MEDICAL EDUCATION AND A MEDICAL/SCIENTIFIC THINK TANK FOR EVIDENCE-BASED MEDICINE IN THE PREVENTION, TREATMENT AND MAINTENANCE OF PATIENTS AT RISK FOR OR AFFLICTED WITH INVASIVE FUNGAL INFECTIONS WHILE ALSO SERVING AS A RESOURCE AND SUPPORT FOR PATIENTS AND CAREGIVERS WHO ARE AFFECTED BY THESE SERIOUS RARE DISEASES.

🔒

Trantor Score

Financial Health & Payment Capacity Assessment (FICO Scale: 300–850)

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $462,510

Program Service Revenue $0

Investment Income $5,391

Other Revenue $2,836

TOTAL REVENUE $470,737

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $330,728

Other Expenses $398,802

TOTAL EXPENSES $398,802

Year-over-Year Comparison

	2024	2023	Change
Revenue	$470,737	$120,548	+2.9%
Expenses	$398,802	$146,968	+1.7%
Net Income	$71,935	$-26,420	-3.7%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$26,400

Total Directors

$26,400

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
LUIS OSTROSKY-ZEICHNER MD	IMMEDIATE PAST PRESIDENT	3.00	Officer Director	$0	$0	$0
DIMITRIOS KONTOYIANNIS MD	PRESIDENT	5.00	Officer Director	$0	$0	$0
MARISA MICELI MD	TREASURER	3.00	Officer Director	$0	$0	$0
ILAN SCHWARTZ	SECRETARY	3.00	Officer Director	$0	$0	$0
JOHN BADDLEY	BOARD MEMBER	2.00	Director	$0	$0	$0
TOM PATTERSON	BOARD MEMBER	2.00	Director	$0	$0	$0
MONICA SLAVIN	BOARD MEMBER	2.00	Director	$0	$0	$0
JOE VAZQUEZ	BOARD MEMBER	2.00	Director	$0	$0	$0
GEORGE THOMPSON	PRESIDENT ELECT	3.00	Director	$0	$0	$0
CAROLYNN THOMAS JONES	EXECUTIVE DIRECTOR (NON-VO	5.00	Officer Director	$26,400	$0	$26,400
JULIA MESSINA	BOARD MEMBER	2.00	Director	$0	$0	$0
ANDREJ SPEC	BOARD MEMBER	2.00	Director	$0	$0	$0
PASCHALIS VERGIDIS	BOARD MEMBER	2.00	Director	$0	$0	$0
THOMAS WALSH	BOARD MEMBER	2.00	Director	$0	$0	$0
PETER PAPPAS	BOARD MEMBER (NON-VOTING)	2.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$470,737	$398,802	$476,880	$71,935
2023	$120,548	$146,968	$422,723	$-26,420
2022	$393,086	$375,141	$379,143	$17,945
2021	$153,473	$133,404	$469,190	$20,069
2020	$182,603	$160,392	$341,129	$22,211
2019	$247,775	$168,518	$318,918	$79,257
2018	$383,764	$251,506	$239,661	$132,258

MYCOSES STUDY GROUP EDUCATION AND RESEARCH CONSORTIUM